DMD Pipeline: After Sarepta’s First-Ever Approval, Are Combinations Next?
Executive Summary
Several companies have DMD drug candidates waiting in the wings to follow Sarepta’s Exondys 51 into the commercial market after FDA approval of the exon-skipping therapy, which could be the backbone for future combination treatment regimens.